FDA says recalled blood thinner sold across the US is unlikely to cause serious harm

A recalled generic blood thinner has drawn national attention. But the U.S. Food and Drug Administration says the problem is not expected to lead to serious health harm.

The update came after the FDA reviewed certain recalled generic dabigatran etexilate products, The Healthy reported.

What happened?

Major Pharmaceuticals distributed the affected medication nationwide, and the July 17 recall covered two strengths of generic dabigatran etexilate made by New Jersey-based Ascend Laboratories.

The recalled items included 5,460 bottles and were a 150-milligram 60-count carton and 75-milligram cartons in 30-count and 60-count sizes. Testing at the 12-month storage mark found "degradation" and impurity levels outside the product's specifications.

Each recalled package carries lot number 25141583 and an expiration date of April 30, 2027. The FDA categorized the action as a Class III recall on August 5, which is the agency's lowest risk level.

The product failed to meet quality requirements, but the agency doesn't expect it to cause serious health effects for most people who take it.

Why does it matter?

Blood thinners are not casual, over-the-counter medications. They are prescribed to prevent dangerous blood clots and must be taken exactly as directed by a healthcare professional.

Even when a recall is labeled low risk, it can confuse for patients who rely on a medication every day. Some people may worry they should stop taking it right away, while others may not realize their bottle is part of the affected lot, so consulting a pharmacist or physician is always the best advice in these moments.

Not every recall signals an emergency. The FDA's classification system helps patients and providers gauge how serious a problem is, and in this case, the agency's review points to a quality issue rather than an immediate threat of serious harm.

Because anticoagulants can raise the risk of excessive bleeding, any question involving a blood thinner deserves careful, medically guided handling.

What can I do?

If you take generic dabigatran etexilate, check your packaging first. Look for lot number 25141583 and the April 30, 2027, expiration date on 150-milligram 60-count cartons or 75-milligram 30-count and 60-count cartons.

A pharmacist or healthcare provider can confirm if a replacement is needed, so reach out if your package matches the recalled lot and expiration date. Getting guidance early can also help prevent any gap in treatment.

Don't change your medication on your own unless a qualified clinician tells you to do so. Stopping a blood thinner without guidance carries its own risks, especially for people taking it to reduce the chance of stroke or clotting complications.

Keep prescription packaging until the medication is finished, check official recall notices for drugs you use, and ask a pharmacist if anything is unclear.

The FDA's message offers some reassurance: this is "a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences."

Get TCD's free newsletters for easy tips, smart advice, and a chance to earn $5,000 toward home upgrades. To see more stories like this one, change your Google preferences here.